Updated September 3, 2020 Revi …
Read News ArticleCategory: Latest News
FDA Approves Generic Version of Tecfidera®, Taken Orally for MS
Reviewed by MSAA Chief Medical …
Read News ArticleMSAA’s Publications, Website, and Blog Receive National Recognition
The Multiple Sclerosis Associa …
Read News ArticleThe Multiple Sclerosis Association of America and Wondros Launch COVID-19 and MS Pathfinder
In an effort to provide accura …
Read News ArticleStatement from MSAA
The Multiple Sclerosis Association of America advocates equally for all members of the MS community, and supports all peaceful efforts aimed at erasing the inequalities that exist between people of different races, religions, gender, and economic backgrounds, as well as those with disabilities. MSAA recognizes the inequities and overwhelming pain associated with discrimination and senseless acts of injustice.
Read News ArticleLaunch of Zeposia® Announced
Reviewed by MSAA Chief Medical …
Read News ArticleResources Available from the Multiple Sclerosis Association of America Amidst the COVID-19 Pandemic
Challenges presented by the CO …
Read News ArticleBafiertam™ Oral Capsules Approved by the FDA for Relapsing Forms of MS
On April 30, 2020, Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced the United States Food and Drug Administration (FDA) approval of Bafiertam™ (monomethyl fumarate) delayed-release oral capsules to treat relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Banner has not yet announced when the medication will be available to the MS community.
Read News ArticleFDA Approves Zeposia® (ozanimod) for the Treatment of Relapsing Forms of MS
Reviewed by MSAA Chief Medical …
Read News ArticleThe Coronavirus and MS: What You Need to Know
The “coronavirus disease 2019” (COVID-19) is a potentially serious respiratory disease that was first reported in December 2019 in China. As of early March 2020, the illness had made its way to almost 70 locations, including the United States, and has affected more than 90,000 individuals worldwide. Please be aware that these figures are expected to increase on a weekly or even a daily basis.
Read News Article